SEATTLE, Wash. (PRWEB) August 07, 2018
Nativis, Inc., a clinical-stage life science therapeutic device company developing non-sterile, non-invasive, non-ionizing and non-thermal treatments for cancers and other serious diseases, announced today that Andrew Daniels has been appointed to its board of directors effective immediately.
Daniels is a seasoned business executive and successful entrepreneur, an active angel investor, and serves on multiple governing boards with companies in the areas of venture capital, wealth management agriculture, health care, technology innovation, commodity trading and AI-driven global hedge fund trading. He has invested in dozens of early-stage companies and recently founded Kronus Innovations, a bio-agricultural company specializing in tailored applications using ultra-low radio frequency energy (ulRFE) technology to improve efficiencies in plant science, animal health and bio-fuels. He serves on the Board of Directors for Pendleton Square Trust Company in Chattanooga, Tennessee and Capitalogix Trading in Coppell, Texas and he serves as a regional board member for St. Jude Children’s Research Hospital.
“We are very excited to welcome Andy Daniels to our board,” stated Chris Rivera, Nativis chief executive officer. “Andy’s extensive professional accomplishments will provide Nativis with a broad range of experience in venture capital, agriculture, health care and technology. As we develop our technology for the treatment of cancer and other serious diseases, it is critical to have board members like Andy as Nativis advances its technology for commercialization in the near future.”
Daniels added, “I am excited to join the Nativis board and look forward to helping guide the company through the development of its unique technology platform. Nativis’ ulRFE® technology represents an unprecedented opportunity to advance a new wave of treatment for recurrent glioblastoma and other health care indications, and I believe that with the right resources and strategies, the company is well-positioned for future success.”
About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, Washington, Nativis is a clinical-stage therapeutic device company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ulRFE to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-sterile, non-invasive, non-ionizing and non-thermal device called Nativis Voyager® system. The company’s goal is to transform disease treatment on a global scale with ulRFE, which can potentially be applied to a wide range of medical conditions, as well as to veterinary medicine and non-medical applications. Nativis’ initial focus is on the treatment of patients with brain cancer, who are not well served by conventional standard of care therapies, often resulting in poor outcomes and devastating side effects. Additional pre-clinical work is focused on exploring new applications in oncology and pain treatment. Nativis Voyager® system is an investigational medical device, limited by U.S. law to investigational use only.
Media Relations Contact: